Multi-Center Real-World Implementation Outcomes of Lenacapavir for HIV Pre-Exposure Prophylaxis

Authors

• Aniruddha Hazra, University of Chicago, Chicago, IL
• Philip A. Chan, Rhode Island Public Health Institute, Providence, RI
• Meredith Clement, LSU Health Sciences Center - New OrleansFollow
• Christopher J. Kaperak, University of Chicago, Chicago, IL
• Hussein Safa, Jefferson Einstein Philadelphia, Philadelphia, PA
• Joshua P. Havens, University of Nebraska Medical Center, Omaha, NE
• Sandra A. Springer, Yale School of Medicine, New Haven, CT
• Jill Blumenthal, University of California San Diego, San Diego, CA
• Matthew Spinelli, University of California San Francisco, San Francisco, CA
• Susanne Doblecki-Lewis, University of Miami Miller School of Medicine, Miami, FL
• Ami Multani, Fenway Health, Boston, MA
• June Gipson, My Brother's Keeper Inc., Ridgeland, MS
• Joesph Cherabie, Washington University in St. Louis, St. Louis, MO
• Rona Vail, Callen-Lorde Community Health Center, New York, NY
• Stephen Sukumaran, Callen-Lorde Community Health Center, New York, NY
• Chase A. Cannon, University of Washington, Seattle, WA
• Rebecca Lillis, LSU Health Sciences Center - New OrleansFollow
• Isolde Butler, CrescentCare, New Orleans, LA
• Christian Turner, Yale School of Medicine, New Haven, CT
• Ellen Taraschi, Maine Family Planning, Augusta, ME
• Gilianne Narcisse-Cempini, University of Miami Miller School of Medicine, Miami, FL
• Leah Kunzmann, Rhode Island Public Health Institute, Providence, RI
• Romini Smith, Fenway Health, Boston, MA
• Drew Halbur, Howard Brown Health, Chicago, IL
• Rupa R. Patel, Whitman-Walker Health, Washington, DC

Document Type

Article

Publication Date

5-15-2026

Publication Title

Clinical Infectious Diseases

Abstract

Lenacapavir PrEP implementation across 17 U.S. sites (n=501) was characterized by delays in initiation driven by payer processes. Early non-persistence was uncommon (3.6%) but exceeded clinical trial discontinuation rates and was strongly associated with abdominal injections and injection-site reactions requiring clinical contact, underscoring modifiable clinical and structural barriers to early persistence.

PubMed ID

42140742

Rights

© The Author(s) 2026. Published by Oxford University Press on behalf of Infectious Diseases Society of America

Recommended Citation

Hazra, Aniruddha; Chan, Philip A.; Clement, Meredith; Kaperak, Christopher J.; Safa, Hussein; Havens, Joshua P.; Springer, Sandra A.; Blumenthal, Jill; Spinelli, Matthew; Doblecki-Lewis, Susanne; Multani, Ami; Gipson, June; Cherabie, Joesph; Vail, Rona; Sukumaran, Stephen; Cannon, Chase A.; Lillis, Rebecca; Butler, Isolde; Turner, Christian; Taraschi, Ellen; Narcisse-Cempini, Gilianne; Kunzmann, Leah; Smith, Romini; Halbur, Drew; and Patel, Rupa R., "Multi-Center Real-World Implementation Outcomes of Lenacapavir for HIV Pre-Exposure Prophylaxis" (2026). School of Medicine Faculty Publications. 4859.
https://digitalscholar.lsuhsc.edu/som_facpubs/4859
10.1093/cid/ciag316